Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
نویسندگان
چکیده
منابع مشابه
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
PURPOSE Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteolytic tumor in which bone destruction is mediated by RANK ligand (RANKL). The RANKL inhibitor denosumab is being investigated for treatment of GCTB. We describe histologic analyses of GCTB tumor samples from a phase II study of denosumab in GCTB. EXPERIMENTAL DESIGN Adult patients with recurrent or unresectable GCTB ...
متن کاملCancer Therapy: Clinical Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Purpose:Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteolytic tumor in which bone destruction is mediated by RANK ligand (RANKL). The RANKL inhibitor denosumab is being investigated for treatment of GCTB. We describe histologic analyses of GCTB tumor samples from a phase II study of
متن کاملGiant cell tumor of the sphenoid bone
Background: Giant cell tumor is a benign but locally aggressive bone neoplasm which uncommonly involves the skull. Giant cell tumor (GCT) of the sphenoid bone is relatively rare. In this report, we describe a tumor of the greater wing of left sphenoid bone. Case presentation: A 31-year-old female was presented with headache, proptosis and diplopia of her left eye. Cranial magnetic resonance ima...
متن کاملGiant Cell Tumor of Bone - an Overview
Giant Cell tumors (GCT) are benign tumors with potential for aggressive behavior and capacity to metastasize. Although rarely lethal, benign bone tumors may be associated with a substantial disturbance of the local bony architecture that can be particularly troublesome in peri-articular locations. Its histogenesis remains unclear. It is characterized by a proliferation of mononuclear stromal ...
متن کاملA Recurrent Giant Cell Tumor of Bone Treated with Denosumab
Although the giant cell tumor of bone is generally classified as a benign tumor it can rarely metastasize and has a potential risk of local recurrence. We want to report about a female patient who suffered from a recurrence of a giant cell tumor of bone after the implantation of a total endoprosthesis of the knee joint. We have treated her with denosumab, which is a receptor activator of nuclea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2012
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-12-0578